Abdullah Alsuwaidan
YOU?
Author Swipe
View article: Pharmacogenomic testing implementation: Tertiary care center experience and results of a pilot of 512 patients
Pharmacogenomic testing implementation: Tertiary care center experience and results of a pilot of 512 patients Open
Our work describes the successful implementation of PGx testing in clinical practice and encourages further research on improving patient outcomes. Moreover, we describe the major challenges at each step of our approach, which provides our…
View article: Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population
Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population Open
Introduction AML genome in the western populations has provided pathogenetic insights, prognosticators and selection of appropriate therapies. AML genome in the Middle East may differ from that in the west, because of younger population, r…
View article: Flow Cytometric Features in Double/Triple Hit Lymphomas: Dim CD45 Expression of Limited Diagnostic Utility
Flow Cytometric Features in Double/Triple Hit Lymphomas: Dim CD45 Expression of Limited Diagnostic Utility Open
Thank you for your interest in our recently published article of “bright CD38 expression by flow cytometric analysis is a biomarker for double/triple hit lymphomas (DH/THL) with a moderate sensitivity and high specificity” 1. The case desc…
View article: Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity
Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity Open
Background High‐grade B‐cell lymphomas (HGBCL) with MYC and BCL2 or/and BCL6 rearrangements (R), so‐called double/triple‐hit lymphomas (DH/THL), are uncommon, clinically aggressive lymphomas that require a prompt diagnosis. We aim to ident…
View article: Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma
Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma Open
Liver cancer is the sixth most common cancer worldwide and 3rd most common cause of cancer-related death. Hepatocellular carcinoma (HCC) represents more than 90% of primary liver cancer and is a major public health problem. Due to the adva…